Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Allergan

Status and phase: Completed; Phase 3

Conditions: Eyebrow Hypotrichosis

Treatments: Drug: Vehicle to bimatoprost solution; Drug: bimatoprost solution

Study type: Interventional

Funder types: Industry

Identifiers

NCT01765764

192024-043

Details and patient eligibility

About

This study will evaluate the safety and efficacy of bimatoprost solution compared with vehicle in the treatment of eyebrow hypotrichosis (inadequate eyebrows).

Enrollment: 357 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Adult participants with eyebrow hypotrichosis (inadequate eyebrow growth).

Exclusion criteria

• Patients with disease, infection, or abnormality of the eyebrow area
• Patients with permanent eyebrow loss due to over-grooming

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

357 participants in 3 patient groups, including a placebo group

Bimatoprost Solution BID

Experimental group

Description:

Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.

Treatment:

Drug: bimatoprost solution

Bimatoprost Solution QD

Experimental group

Description:

Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.

Treatment:

Drug: Vehicle to bimatoprost solution

Drug: bimatoprost solution

Vehicle to Bimatoprost Solution BID

Placebo Comparator group

Description:

Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.

Treatment:

Drug: Vehicle to bimatoprost solution